XXI Annual Meeting of the International Committee on Thrombosis and Haemostasis

• References

• 1 Deutsch E, Brinkhous K. M, Lechner K, Hinnom S. eds. 1974; Thrombosis: Pathogenesis and Clinical Trials. Thrombosis et Diathesis Haemorrhagica Suppi 59 p. 352.
• 2 Koller F. The physiological function of heparin. p. 17.
• 3 Kiss J. Chemistry of heparin — a short review on recent chemical trends. p. 20.
• 4 Estes J. W, Poulin P. F. Pharmacokinetics of heparin - distribution and elimination. p. 26.
• 5 Abildgaard U. Heparin cofactor and antithrombin. p. 38.
• 6 Yin E. T. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor. p. 43.
• 7 Rosenberg R. D. The effect of heparin on factor XIa and plasmin. p. 51.
• 8 Zucker M. B. Effect of heparin on platelet function. p. 63.
• 9 Lüscher E. F, Kaser-Glanzmann R. Platelet heparin-neutralizing factor platelet factor. 4 p. 66.
• 10 Markwardt F. Antilipemic action of heparin. p. 73.
• 11 Godal H. C. Heparin assay methods for control of in vivo heparin effects. p. 77.
• 12 Wessler S. Small doses of heparin and a new concept of hypercoagulability. p. 81.
• 13 Kakkar V. V. Low dose heparin in the prevention of venous thromboembolism. Rationale and results. p. 87.
• 14 McNicol G. P. Conventional uses of heparin. p. 97.
• 15 Nyman D, Thurnherr N, Duckert F. Heparin dosage in extracorporeal circulation and its neutralization. p. 102.
• 16 Lasch H. G, Heene D. H. Heparin therapy of diffuse intravascular coagulation DIC. p. 105.
• 17 Straub P. W. A case against heparin therapy of intravascular coagulation. p. 107.
• 18 Saliba M. J, Saliba R. J. Heparin in burns - dose related and dose dependent effects. p. 113.
• 19 Brinkhous K. M. XX annual meeting of the International Committee on Thrombosis and Haemostasis. p. 124.
• 20 Blombäck B. Report of the Subcommittee on Nomenclature. p. 126.
• 21 Abildgaard U. Report of the Task Force on Inhibitors of Blood Coagulation. p. 127.
• 22 Blombäck B. Report of the Task Force on Nomenclature of Fibrinogen-Fibrin Degradation Products. p. 141.
• 23 Ménaché D. Report of the Task Force on Clinical Use of factor IX Concentrates. p. 597.
• 24 Ménaché D. Factor IX concentrates. p. 600.
• 25 Hoofnagle J. H, Aronson D, Roberts H. Serologic evidence for hepatitis B virus infection in patients with hemophilia B - a multicenter study. p. 606.
• 26 Roberts H. R, Blatt P. M. Post-transfusion hepatitis following the use of prothrombin complex concentrates. p. 610.
• 27 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. Potentially thrombogenic materials in factor IX concentrates. p. 617.
• 28 Cash J. D, Dalton R. G, Middleton S, Smith J. K. Studies on the thrombo-genicity of Scottish factor IX concentrates in dogs. p. 632.
• 29 Kasper C. K. Thromboembolic complications. p. 642.
• 30 Ménaché D, Roberts H. R. Summary report and recommendations of the Task Force members and consultants. p. 645.
• 31 Day H. J, Holmsen H, Zucker M. B. Methods for separating platelets from plasma. p. 648.
• 32 Verstraete M. Registry of prospective clinical trials. p. 655.